Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xindilimab + bevacizumab + albumin-bound paclitaxel for second-line upper gastrointestinal neuroendocrine carcinoma
ChiCTR2500096757Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab and paclitaxel in neuroendocrine carcinoma (NEC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
sintilimabbevacizumabpaclitaxel
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on ChiCTR2500096757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096757.